Core Laboratories N.V.
NYSE:CLBOil & Gas Equipment & Services
+$0.12 today
- Market cap
- $387.21M
- Beta
- 0.99
- P/E (TTM)
- 18.3
- EPS (TTM)
- $0.63
- Dividend yield
- 0.35%
Volume 0.52M
Average 0.49M
CLB Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Core Laboratories N.V.NYSE: CLB
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures growth accelerates
Q1 FY2026 capital expenditures of $4.89M (cash outflow) rose 36.7% year over year, ahead of the +19.3% change in trailing-twelve-month capital expenditures. Sequentially, it rose 35.6% from the prior quarter. Over 3 fiscal years it compounded at +12.6% a year.
Context
- Capital expenditures amounted to 2.8% of revenue in FY2025, up 0.3 pp from a year earlier.
- Capital expenditures grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +36.7% holds above the trailing-twelve-month pace of +19.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (14.59M) USD
- Year-over-year change
- -12.0%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (14.59M) | -12.0% |
| FY2024 | 2024-12-31 | (13.03M) | -23.1% |
| FY2023 | 2023-12-31 | (10.58M) | -3.6% |
| FY2022 | 2022-12-31 | (10.22M) | +24.5% |
| FY2021 | 2021-12-31 | (13.54M) | — |
Capital Expenditures vs competitors
How CLB compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +19.3% is the 3rd highest of 10, against a peer median of -0.3%.
- Capital expenditures amounts to 3.1% of revenue for CLB, versus a peer median of 30.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $715.95M USD | +14.0% | +24.2% | 22.2% | |
| LTM Mar 2026 | $425.7M USD | -32.5% | -26.4% | 55.2% | |
| LTM Mar 2026 | $387.71M USD | +3.1% | +21.3% | 85.1% | |
| LTM Mar 2026 | $282.3M USD | -32.1% | +14.3% | 26.9% | |
| LTM Mar 2026 | CA$268.61M CAD | +21.5% | +12.6% | 14.3% | |
| LTM Mar 2026 | $264.54M USD | -0.3% | +60.9% | 74.4% | |
| LTM Mar 2026 | $245.69M USD | +81.2% | — | 19330.6% | |
| LTM Mar 2026 | $84.49M USD | -25.5% | -95.4% | 30.7% | |
| LTM Mar 2026 | $29.04M USD | -4.2% | +5.6% | 0.8% | |
| LTM Mar 2026 | $16.16M USD | +19.3% | +12.6% | 3.1% | |
| Peer median (excluding CLB) | — | -0.3% | +13.5% | 30.7% | |
Competitors are the stored peer set for CLB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 20.22M | 19.66M | 37.03M | 32.15M | 31.8M |
| Depreciation & Amortization | 18.52M | 17.16M | 15.78M | 14.95M | 14.65M |
| Deferred Income Tax | 6.01M | 433K | (10.81M) | 674K | (4.74M) |
| Stock-Based Compensation | 19.09M | 7.76M | 13.97M | 3.76M | 7.14M |
| Change in Working Capital | (24.25M) | (25.02M) | (28.77M) | 7.88M | (5.57M) |
| Accounts Receivables | (13.52M) | (10.08M) | (2.62M) | (3.61M) | (4.95M) |
| Inventory | (4.55M) | (14.86M) | (12.98M) | 9.37M | 2.64M |
| Accounts Payables | 6.57M | 15.37M | (12.88M) | 519K | 477K |
| Other Working Capital | (12.75M) | (15.46M) | (300K) | 1.61M | (3.73M) |
| Other Non-Cash Items | (3.01M) | 4.97M | (2.41M) | (3.03M) | (6.11M) |
| Operating Cash Flow | 36.58M | 24.96M | 24.79M | 56.39M | 37.18M |
| Capital Expenditures | (13.54M) | (10.22M) | (10.58M) | (13.03M) | (14.59M) |
| Acquisitions (Net) | 873K | 240K | 0 | 0 | (1.24M) |
| Purchases of Investments | 13.54M | 0 | 0 | 0 | 0 |
| Sales of Investments | 726K | 0 | 0 | 0 | 0 |
| Other Investing Activities | (11.82M) | 6.12M | 3.93M | 6.63M | 13.6M |
| Investing Cash Flow | (10.22M) | (3.86M) | (6.65M) | (6.39M) | (2.23M) |
| Debt Repayment | (71M) | (15M) | (9M) | (38M) | (16.71M) |
| Common Stock Issued | 60M | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | (8.26M) | (3.9M) | (2.2M) | (5.31M) | (12.43M) |
| Dividends Paid | (1.83M) | (1.85M) | (1.87M) | (1.88M) | (1.87M) |
| Other Financing Activities | (1.37M) | (2.62M) | (5.38M) | (775K) | (254K) |
| Financing Cash Flow | (22.46M) | (23.38M) | (18.45M) | (45.96M) | (31.26M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 3.9M | (2.28M) | (308K) | 4.04M | 3.69M |
| Free Cash Flow | 23.04M | 14.74M | 14.21M | 43.36M | 22.59M |
Core Laboratories N.V.
NYSE:CLB
Intrinsic Alpha fair value
Locked
Current Price
$8.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.